Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Breast Neoplasms 5Melanoma 4Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Vaginal Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Stomach Neoplasms 2Penile Neoplasms 2Papillomavirus Infections 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anus Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Mesothelioma 1

Interventions

pembrolizumab 9Nivolumab 5fludarabine 4Cyclophosphamide 4amatuximab 3Ipilimumab 3Fluorouracil 3Cisplatin 3tislelizumab 2spartalizumab 2budigalimab 2belinostat 2Hyperthermic Intraperitoneal Chemotherapy 2Cytoreduction Surgical Procedures 2Carboplatin 2venetoclax 1talazoparib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1atezolizumab 1aldesleukin 1Valacyclovir 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × fludarabine phosphate × Gynecologic × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡